Limits...
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y - Cancer Sci. (2014)

Bottom Line: High levels of c-MET expression (c-MET-high) in the primary tumors were observed in 52% of patients.Relapse-free survival was significantly shorter for patients with c-MET-high primary tumors (9.7 months) than for those with c-MET-low primary tumors (21.1 months) (P = 0.013).These results suggest that a high level of genetic concordance in KRAS, BRAF and PIK3CA between primary tumors and liver metastases, and c-MET-high in the primary tumors were associated with shorter relapse-free survival after hepatic metastasectomy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Representative images of c-MET expression: 3, strongly positive immunostaining; 2, medium positive immunostaining; 1, negative staining with focally very weak immunoreactivity; 0, no membranous reactivity or only interstitial or cytoplasmic reactivity in any tumor cell.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317860&req=5

fig01: Representative images of c-MET expression: 3, strongly positive immunostaining; 2, medium positive immunostaining; 1, negative staining with focally very weak immunoreactivity; 0, no membranous reactivity or only interstitial or cytoplasmic reactivity in any tumor cell.

Mentions: c-MET expression was assessed by IHC in primary tumors and liver metastases expression in all 108 specimens. c-MET staining intensity in the primary tumors was 3 in 7 cases (6%), 2 in 49 cases (45.8%), 1 in 51 cases (47.2%) and negative in 1 case (0.9%). c-MET staining intensity in the liver metastases was 3 in 4 cases (3.7%), 2 in 55 cases (51.9%), 1 in 45 cases (41.7%) and negative in four cases (3.7%) (Fig. 1).


Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.

Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y - Cancer Sci. (2014)

Representative images of c-MET expression: 3, strongly positive immunostaining; 2, medium positive immunostaining; 1, negative staining with focally very weak immunoreactivity; 0, no membranous reactivity or only interstitial or cytoplasmic reactivity in any tumor cell.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317860&req=5

fig01: Representative images of c-MET expression: 3, strongly positive immunostaining; 2, medium positive immunostaining; 1, negative staining with focally very weak immunoreactivity; 0, no membranous reactivity or only interstitial or cytoplasmic reactivity in any tumor cell.
Mentions: c-MET expression was assessed by IHC in primary tumors and liver metastases expression in all 108 specimens. c-MET staining intensity in the primary tumors was 3 in 7 cases (6%), 2 in 49 cases (45.8%), 1 in 51 cases (47.2%) and negative in 1 case (0.9%). c-MET staining intensity in the liver metastases was 3 in 4 cases (3.7%), 2 in 55 cases (51.9%), 1 in 45 cases (41.7%) and negative in four cases (3.7%) (Fig. 1).

Bottom Line: High levels of c-MET expression (c-MET-high) in the primary tumors were observed in 52% of patients.Relapse-free survival was significantly shorter for patients with c-MET-high primary tumors (9.7 months) than for those with c-MET-low primary tumors (21.1 months) (P = 0.013).These results suggest that a high level of genetic concordance in KRAS, BRAF and PIK3CA between primary tumors and liver metastases, and c-MET-high in the primary tumors were associated with shorter relapse-free survival after hepatic metastasectomy.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus